NewLink gets $1M Ebola study contract

|About: NewLink Genetics Corpo... (NLNK)|By:, SA News Editor

The U.S. Defense Threat Reduction Agency (DTRA) issues a $1M letter contract to NewLink Genetics (NASDAQ:NLNK) subsidiary BioProtection Systems Corp. for studies supporting the advancement of an Ebola vaccine licensed from the Public Health Agency of Canada. The contract will fund the pre-clinical toxicology studies that will enable an IND application and also includes the manufacture of clinical materials.